Beyond BCG: The potential for a more effective TB vaccine

Molecular Medicine Today

Volumn 5, Issue 11, 1999, Pages 487-492

  Orme, Ian M ^a  

^a Immunology and Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; RECOMBINANT VACCINE; VACCINE;

BCG VACCINATION; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; HUMAN; NONHUMAN; REVIEW; TREATMENT OUTCOME; TUBERCULOSIS; VACCINE PRODUCTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; BACTERIAL VACCINES; BCG VACCINE; CHILD; CLINICAL TRIALS; FORECASTING; GENETIC VECTORS; GUINEA PIGS; HEALTH POLICY; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; T-LYMPHOCYTE SUBSETS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0033231909     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01594-4     Document Type: Review

References (48)

1. Grange J.M.et al. What is BCG? Tubercle. 64:1983;129-139.
2. Huebner R.E. BCG vaccination in the control of tuberculosis. Curr. Top. Microbiol. Immunol. 215:1996;263-282.
3. Kochi A., Vareldzis B., Styblo K. Multidrug-resistant tuberculosis and its control. Res. Microbiol. 144:1993;104-110.
4. Bloom B.R., Murray C.J. Tuberculosis: commentary on a reemergent killer. Science. 257:1992;1055-1064.
5. Raviglione M.C., Snider D.E. Jr., Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. J. Am. Med. Assoc. 273:1995;220-226.
6. Raviglione M.C., Dye C., Schmidt S., Kochi A. Assessment of worldwide tuberculosis control. WHO global surveillance and monitoring project. Lancet. 350:1997;624-629.
7. Rodrigues L.C., Smith P.G. Tuberculosis in developing countries and methods for its control. Trans. R. Soc. Trop. Med. Hyg. 84:1990;739-744.
8. McMurray D.N., Collins F.M., Dannenberg A.M. Jr., Smith D.W. Pathogenesis of experimental tuberculosis in animal models. Curr. Top. Microbiol. Immunol. 215:1996;157-179.
9. Orme I.M., Collins F.M. Mouse model of tuberculosis. Bloom B.R. Tuberculosis; Pathogenesis, Protection, and Control. 1994;113-134 ASM Press.
10. Orme I.M. Immunity to Mycobacteria. 1995;RG Landes.
11. Orme I.M. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J. Immunol. 138:1987;293-298.
12. Flynn J.L.et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:1993;2249-2254.
13. Cooper A.M.et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178:1993;2243-2247.
14. Orme I.M. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect. Immun. 56:1988;3310-3312.
15. Orme I.M. Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. J. Immunol. 140:1988;3589-3593.
16. Russell D.G. Intracellular parasitism: the contrasting styles of Leishmania and Mycobacterium. Russell D.G. Strategies for Intracellular Survival of Microbes. 1994;227-243 Ballierre Tindall.
17. Rhoades, E.R., Cooper, A.M. and Orme, I.M. (1995) Chemokine response in mice infected with Mycobacterium tuberculosis. Infect. Immun. 63, 3871-3877.
18. Johnson C.M., Cooper A.M., Frank A.A., Orme I.M. Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Infect. Immun. 66:1998;1666-1670.
19. Smith D.W. Protective effect of BCG in experimental tuberculosis. Adv. Tuberc. Res. 22:1985;1-97.
20. Wiegeshaus E., Balasubramanian V., Smith D.W. Immunity to tuberculosis from the perspective of pathogenesis. Infect. Immun. 57:1989;3671-3676.
21. Tripathy S.P. Fifteen year follow-up of the Indian BCG prevention trial. Bull. Int. Union Tubercle Lung Dis. 62:1987;69-72.
22. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. Tubercle Lung Dis. 75:1994;179-180.
23. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. Morb. Mortal. Wkly Rep. 45:1996;1-18.
24. Tala E.O., Tala-Heikkila M.M. Pros and cons of BCG vaccination in countries with low incidence of tuberculosis. Infect. Control Hosp. Epidemiol. 15:1994;497-499.
25. Vanderschueren S., Peetermans W., Bobbaers H. Is BCG vaccination against tuberculosis still indicated? Acta Clin. Belg. 49:1994;138-147.
26. Roche P.W., Triccas J.A., Winter N. BCG vaccination against tuberculosis: past disappointments and future hopes. Trends Microbiol. 3:1995;397-401.
27. Watson J.M. BCG - mass or selective vaccination? J. Hosp. Infect. 30:1995;508-513.
28. Baldwin S.L.et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66:1998;2951-2959.
29. Orme I.M. The immunopathogenesis of tuberculosis: a new working hypothesis. Trends Microbiol. 6:1998;94-97.
30. Huygen K.et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med. 2:1996;893-898.
31. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62:1994;2536-2544.
32. Hubbard R.D., Flory C.M., Collins F.M. Immunization of mice with mycobacterial culture filtrate proteins. Clin. Exp. Immunol. 87:1992;94-98.
33. Horwitz M.A., Lee B.W., Dillon B.J., Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1530-1534.
34. Roberts A.D.et al. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology. 85:1995;502-508.
35. Bange F.C., Brown A.M., Jacobs W.R. Jr. Leucine auxotrophy restricts growth of Mycobacterium bovis BCG in macrophages. Infect. Immun. 64:1996;1794-1799.
36. Guleria I.et al. Auxotrophic vaccines for tuberculosis. Nat. Med. 2:1996;334-337.
37. McAdam R.A.et al. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis. Infect. Immun. 63:1995;1004-1012.
38. Gicquel B. BCG as a vector for the construction of multivalent recombinant vaccines. Biologicals. 23:1995;113-118.
39. Hanson M.S., Lapcevich C.V., Haun S.L. Progress on development of the live BCG recombinant vaccine vehicle for combined vaccine delivery. Ann. New York Acad. Sci. 754:1995;214-221.
40. Hanson M.S.et al. Efficacy and safety of live recombinant BCG vaccines. Dev. Biol. Stand. 84:1995;229-236.
41. Stover C.K.et al. New use of BCG for recombinant vaccines. Nature. 351:1991;456-460.
42. Murray P.J., Aldovini A., Young R.A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines. Proc. Natl. Acad. Sci. U. S. A. 93:1996;934-939.
43. Aldovini A., Young R.A. Development of a BCG recombinant vehicle for candidate AIDS vaccines. Int. Rev. Immunol. 7:1990;79-83.
44. Fuerst T.R., Stover C.K., de la Cruz V.F. Development of BCG as a live recombinant vector system: potential use as an HIV vaccine. Biotechnol. Ther. 2:1991;159-178.
45. Lagranderie M.et al. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res. Hum. Retroviruses. 14:1998;1625-1633.
46. Abou-Zeid C.et al. Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect. Immun. 65:1997;1856-1862.
47. Sterne J.A., Rodrigues L.C., Guedes I.N. Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung Dis. 2:1998;200-207.
48. Bendelac A. CD1: presenting unusual antigens to unusual T lymphocytes. Science. 269:1995;185-186.